EE650 Incremental Costs of Tofacitinib Compared to Adalimumab and Ixekizumab for the Treatment of Active Ankylosing Spondylitis in Denmark

Abstract

Authors

T. Mølbach D. Hauberg K. Kemp

Full Text Cite This Article
Back to Volume 26, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×